Skip to content

Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study

Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01239238
Acronym
RASTER
Enrollment
102
Registered
2010-11-11
Start date
2010-11-30
Completion date
2013-03-31
Last updated
2013-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Children, Exhaled Breath Condensate, Home Monitoring, Non-invasive Inflammatory Markers, Volatile Organic Compounds

Keywords

asthma, children, home monitoring, exhaled breath condensate, non-invasive inflammatory markers, volatile organic compounds

Brief summary

The purpose of the present proposal was to investigate the predictive properties of markers in exhaled breath to predict an asthma exacerbation. In addition, the reliability of home monitor assessments to measure asthma control will be examined.

Interventions

None listed

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

1. already known with a diagnosis of asthma during at least 6 months 2. age between 6 and 17 years 3. reversibility to a bronchodilator (increase in FEV1 \> 9% of predicted value and/or 4. bronchial hyperresponsiveness to histamine \< 8 mg/ml.

Exclusion criteria

1. cardiac abnormalities 2. mental retardation, congenital abnormalities or existence of a syndrome 3. active smoking 4. no technical satisfactory performance of measurements 5. no phone line or internet assess available at home.

Design outcomes

Primary

MeasureTime frameDescription
number of exacerbations1 yearincrease of asthma symptoms, use of short b2-agonists, drop in FEV1% of maximum personal value.
asthma control1 yearasthma control questionnaire
Quality of life1 yearAsthma Quality of Life questionnaire for children

Secondary

MeasureTime frameDescription
cost-effectiveness1 yearincremental cost per exacerbation prevented

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026